Back to today’s briefing

Story perspectives

ImmunityBio's ANKTIVA Revenue Soars 700%, Stock Jumps 12.99%

2/24/2026

31 7 Full Breakdown

Summary

Story summary

ImmunityBio, Inc. reported that ANKTIVA revenue grew 700% in 2025, prompting investor evaluation on February 23, 2026.
The stock rose 12.99% to $9.83 as investors weighed growth against ImmunityBio's losses since its 2015 IPO.
Recent approvals for bladder and lung cancer treatments across multiple countries signal potential for sustained demand.
The stock has quintupled this year, while peers Iovance Biotherapeutics and Krystal Biotech also gained.

1 of 1

Story summary

ImmunityBio, Inc. reported that ANKTIVA revenue grew 700% in 2025, prompting investor evaluation on February 23, 2026.
The stock rose 12.99% to $9.83 as investors weighed growth against ImmunityBio's losses since its 2015 IPO.
Recent approvals for bladder and lung cancer treatments across multiple countries signal potential for sustained demand.
The stock has quintupled this year, while peers Iovance Biotherapeutics and Krystal Biotech also gained.